Advanced Immunotherapeutics Inc is categorized under Medical Research in Irvine, CA and active since 1989.
Advanced Immunotherapeutics Inc was established in 1989, and today employs 1 to 4, earning $1.000.000 to $2.499.999 per year. This is a Medical Research business, which does work in the B2B market, and is classified as a Medical Research, under code number 541720 by the NAICS.
If you are seeking more information, feel free to contact Raj Shrotriya Phd at the company’s single location by writing to 157 Technology Drive, Irvine, California CA 92618 or by phoning (949) 788-6700. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Advanced Immunotherapeutics Inc |
| Contact Person: | Raj Shrotriya Phd |
| Address: | 157 Technology Drive, Irvine, California 92618 |
| Phone Number: | (949) 788-6700 |
| Website Address: | spectrumpharm.com |
| Annual Revenue (USD): | $1.000.000 to $2.499.999 |
| Founded: | 1989 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Medical Research |
| SIC Code: | 8733 |
| NAICS Code: | 541720 |
| Share This Business: |
Advanced Immunotherapeutics Inc was started in 1989 to provide professional Medical Research under the SIC code 8733 and NAICS code 541720. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $1.000.000 to $2.499.999 per annum.
Feel free to contact Raj Shrotriya Phd for inquiries that concern Advanced Immunotherapeutics Inc by calling the company number (949) 788-6700, as your correspondence is most welcome. Additionally, the physical location of the single location of Advanced Immunotherapeutics Inc can be found at the coordinates 33.663341,-117.744518 as well as the street address 157 Technology Drive in Irvine, California 92618.
For its online presence, you may visit Advanced Immunotherapeutics Inc’s website at spectrumpharm.com and engage with its social media outlets through on Twitter and on Facebook.